Alphatec Holdings, Inc.: Form 10-Q for the period ended Jun 30, 2022
Filed with the SEC on Aug 4, 2022 and accepted by EDGAR at Aug 4, 2022, 16:58 ET.
Management's discussion and analysis
As filed, 27,916 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
You should read the following management's discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and the related notes thereto that appear elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto and under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”). In addition to historical information, the following management’s discussion and analysis of our financial condition and results of operations includes forward-looking information that involves risks, uncertainties, and assumptions. Our actual results and the timing of events could differ materially from those anticipated by these forward-looking statements as a result of many factors, such as those set forth under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021, and any updates to those risk factors filed from time to time in our subsequent periodic and current reports filed with the SEC.
Overview
We are a medical technology company focused on the design, development, and advancement of technology for better surgical treatment of spinal disorders. We are dedicated to revolutionizing the approach to spine surgery through clinical distinction. We are focused on developing new approaches that integrate seamlessly with our expanding Alpha InformatiX™ product platform to better inform surgery and to achieve the goals of spine surgery more safely and reproducibly. We have a broad product portfolio designed to address the spine’s various pathologies. Our ultimate vision is to be the standard bearer in spine.
We intend to drive growth by capitalizing on our collective spine experience and investing in the research and development to continually differentiate our solutions and improve spine surgery. We believe our future success will be fueled by introducing market-shifting innovation to the spine market, and that we are well-positioned to capitalize on current spine market dynamics.
We market and sell our products through a network of independent sales agents and direct sales representatives. An objective of our leadership team is to deliver increasingly consistent, predictable growth. To accomplish this, we have partnered more closely with new and existing independent sales agents to create a more dedicated and loyal sales channel for the future. We have added, and intend to continue to add, new high-quality exclusive and dedicated independent sales agents and direct sales representatives to expand future growth. We believe this will allow us to reach an untapped market of surgeons, hospitals, and national accounts across the United States of America and internationally, as well as better penetrate existing accounts and territories.
Revenue and Expense Components
The following is a description of the primary components of our revenue and expenses:
Revenue. We derive our revenue primarily from the sale of spinal surgery implants used in the treatment of spine disorders as well as the sale of medical imaging equipment which is used for surgical planning and post-operative assessment. Spinal implant products include pedicle screws and complementary implants, interbody devices, plates, and tissue-based materials. Medical imaging equipment includes our EOS full-body and weight-bearing x-ray imaging devices, and related services. Our revenue is generated by our direct sales force and independent sales agents. Our products are shipped and invoiced to hospitals and surgical centers. Currently, most of our business is conducted with customers within markets in which we have experience and with payment terms that are customary to our business. We may defer revenue until the time of collection if circumstances related to payment terms, regional market risk or customer history indicate that collectability is not certain.
Cost of sales. Cost of sales consists primarily of direct product costs, royalties, service labor hours, and parts. Our product costs consist primarily of raw materials, component parts, direct labor, and overhead. The product costs of certain of our biologics products include the cost of procuring and processing human tissue. We incur royalties related to the technologies that we license from others and the products that are developed in part by surgeons with whom we collaborate in the product development process.
Research and development expenses. Research and development expenses consist of costs associated with the design, development, testing, and enhancement of our products. Research and development expenses also include salaries and related employee benefits, research-related overhead expenses, fees paid to external service providers and development consultants in the form of both cash and equity.
Sales, general and administrative expenses. Sales, general and administrative expenses consist primarily of salaries and related employee benefits, sales commissions and other variable costs, depreciation of our surgical instruments, regulatory affairs, quality assurance costs, professional service fees, travel, medical education, trade show and marketing costs, and insurance.
Litigation-related expenses. Litigation-related expenses are costs incurred for our ongoing litigation, primarily with NuVasive, Inc.
Amortization of acquired intangible assets. Amortization of acquired intangible assets consists of intangible assets acquired in business combinations and asset purchases.
Transaction-related expenses. Transaction-related expenses are certain costs incurred related primarily to the acquisition and integration of EOS.
Restructuring expenses. Restructuring expenses are costs incurred related primarily to severance, social plan benefits and related taxes in connection with cost rationalization efforts, as well as costs associated with the opening or closing of office and warehouse facilities.
Total interest and other expense, net. Total interest and other expense, net includes interest income, interest expense, gains and losses from foreign currency exchanges and other non-operating gains and losses.
Income tax provision. Income tax provision primarily consists of an estimate of federal, state, and foreign income taxes based on enacted state, and foreign tax rates, as adjusted for allowable credits, deductions, uncertain tax positions, changes in the valuation of our deferred tax assets and liabilities, and changes in tax laws.
Critical Accounting Policies and Estimates
Our discussion and analysis of our financial condition and results of operations is based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States of America. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures. On an on-going basis, we evaluate our estimates and assumptions, including those related to revenue recognition, allowances for accounts receivable, inventories, intangible assets, stock-based compensation, and income taxes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumption conditions.
Critical accounting policies are those that, in management’s view, are most important in the portrayal of our financial condition and results of operations. Management believes there have been no material changes during the three months ended June 30, 2022, to the critical accounting policies discussed in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section of our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC.
Results of Operations
Total revenue
(in thousands, except %)
| Revenue: | Three Months Ended June 30, 2022 | 2021 | Change $% | Six Months Ended June 30, 2022 | 2021 | Change $% | ||
|---|---|---|---|---|---|---|---|---|
| Revenue from products and services | $84,151 | $61,885 | $22,266 | 36% | $155,069 | $105,601 | $49,468 | 47% |
| Revenue from international supply agreement | — | 364 | (364) | (100)% | 15 | 769 | (754) | (98)% |
| Total revenue | $84,151 | $62,249 | $21,902 | 35% | $155,084 | $106,370 | $48,714 | 46% |
Revenue associated with our acquisition of EOS accounted for approximately $5.7 million, or 26%, and $16.0 million, or 32%, of the increase in revenue from products and services for the three and six months ended June 30, 2022, respectively, as compared to the three and six months ended June 30, 2021. Revenue from products and services, excluding EOS, accounted for approximately $16.6 million, or 74%, and $33.5 million, or 68%, of the increase during the three and six months ended June 30, 2022, respectively, as compared to the three and six months ended June 30, 2021. The increase was primarily due to an increase in product volume that was due to the continued expansion of our new product portfolio, increases in our surgeon user base, and progress related to the transformation of our sales network.
Cost of sales
(in thousands, except %)
| Three Months Ended June 30, 2022 | 2021 | Change $% | Six Months Ended June 30, 2022 | 2021 | Change $% | |||
|---|---|---|---|---|---|---|---|---|
| Cost of sales | $28,675 | $21,184 | $7,491 | 35% | $50,392 | $33,447 | $16,945 | 51% |
Cost of sales associated with EOS operations accounted for approximately $4.0 million, or 53%, and $10.1 million, or 60%, of the increase for the three and six months ended June 30, 2022, respectively, as compared to the three and six months ended June 30, 2021. Cost of sales, excluding EOS, accounted for approximately $4.9 million, or 65%, and $8.2 million, or 48%, of the increase during the three and six months ended June 30, 2022, respectively, as compared to the three and six months ended June 30, 2021. The increase was primarily due to product volume, offset by a decrease in inventory expense associated with the purchase accounting of EOS. Inventory expense associated with the purchase accounting of EOS offset the increase by approximately $1.3 million, or 18%, and $1.3 million, or 8%, during the three and six months ended June 30, 2022, respectively, as compared to the three and six months ended June 30, 2021.
Operating expenses
(in thousands, except %)
| Operating expenses: | Three Months Ended June 30, 2022 | 2021 | Change $% | Six Months Ended June 30, 2022 | 2021 | Change $% | ||
|---|---|---|---|---|---|---|---|---|
| Research and development | $10,596 | $7,839 | $2,757 | 35% | $20,318 | $13,640 | $6,678 | 49% |
| Sales, general and administrative | 72,668 | 60,659 | 12,009 | 20% | 142,139 | 101,085 | 41,054 | 41% |
| Litigation-related expenses | 5,495 | 1,167 | 4,328 | 371% | 13,027 | 4,502 | 8,525 | 189% |
| Amortization of acquired intangible assets | 2,177 | 1,208 | 969 | 80% | 4,407 | 1,380 | 3,027 | 219% |
| Transaction-related expenses | — | 4,771 | (4,771) | (100)% | 120 | 5,783 | (5,663) | (98)% |
| Restructuring expenses | 289 | 1,173 | (884) | (75)% | 1,659 | 1,331 | 328 | 25% |
| Total operating expenses | $91,225 | $76,817 | $14,408 | 19% | $181,670 | $127,721 | $53,949 | 42% |
Research and development expenses. Research and development expense associated with EOS accounted for approximately $0.9 million, or 32%, and $2.0 million, or 30%, of the total increase for the three and six months ended June 30, 2022, respectively, as compared to the three and six months ended June 30, 2021. Research and development expense, excluding EOS, accounted for approximately $1.9 million, or 68%, and $4.7 million, or 70%, of the increase during the three and six months ended June 30, 2022, respectively, compared to the three and six months ended June 30, 2021. The increase was primarily due to an increase in personnel to support the expansion of our new product portfolio.
Sales, general and administrative expenses. Sales, general and administrative expenses associated with EOS accounted for approximately $2.6 million, or 21%, and $7.6 million, or 19%, of the total increase for the three and six months ended June 30, 2022, respectively, as compared to the three and six months ended June 30, 2021. Sales, general and administrative expenses, excluding EOS, accounted for approximately $9.4 million, or 79%, and $33.4 million, or 81%, of the increase during the three and six months ended June 30, 2022, respectively, compared to the three and six months ended June 30, 2021. The increase was primarily due to higher compensation-related costs and variable selling expenses associated with the increase in revenue, and our continued investment in building our strategic distribution channel. Additionally, we have increased our investment in our sales and marketing functions by increasing headcount to support the growth of our business, as well as necessary administrative support.
Litigation-related expenses. Litigation expenses increased by $4.3 million, or 371%, and $8.5 million, or 189%, during the three and six months ended June 30, 2022, respectively, as compared to the three and six months ended June 30, 2021. Litigation expense is primarily related to our litigation and settlement with NuVasive, Inc. and other legal activities.
Amortization of acquired intangible assets. The increase in amortization of acquired intangible assets is primarily due to the amortization of intangible assets acquired in the EOS acquisition.
Transaction-related expenses. The decrease in transaction-related expenses for the three and six months ended June 30, 2022, is primarily due to the closing of the EOS acquisition on May 13, 2021.
Restructuring expenses. The decrease in restructuring expenses for the three months ended June 30, 2022 is due to non-recurring costs associated with the opening of our Memphis distribution center and closing costs related to our prior headquarters incurred during the three months ended June 30, 2021. The increase in restructuring expenses for the six months ended June 30, 2022 is due to severance, social plan benefits and related taxes in connection with cost rationalization efforts.
Total interest and other expense, net
(in thousands, except %)
| Interest and other expense, net: | Three Months Ended June 30, 2022 | 2021 | Change $% | Six Months Ended June 30, 2022 | 2021 | Change $% | ||
|---|---|---|---|---|---|---|---|---|
| Interest expense, net | $(1,435) | $(2,394) | $959 | (40)% | $(2,891) | $(4,332) | $1,441 | (33)% |
| Other income (expense), net | 67 | (16) | 83 | (519)% | 37 | (1,905) | 1,942 | (102)% |
| Total interest and other expense, net | $(1,368) | $(2,410) | $1,042 | (43)% | $(2,854) | $(6,237) | $3,383 | (54)% |
The decrease in other income (expense), net for the three months ended June 30, 2022, as compared to the three months ended June 30, 2021, was primarily due to foreign currency gains. The decrease in other income (expense), net, during the six months ended June 30, 2022, as compared to the six months ended June 30, 2021 was primarily due to foreign currency losses related to the forward contract settlement and the net loss on debt extinguishment associated with the early payoff of the term loan and the PPP loan forgiveness, which were non-recurring expenses incurred during the six months ended June 30, 2021. The decrease in interest expense, net, during the three and six months ended June 30, 2022, was primarily due to lower interest rates on the 2026 Notes compared to the Term Loan that was repaid in full during the year ended December 31, 2021.
Income tax provision
(in thousands, except %)
| Three Months Ended June 30, 2022 | 2021 | Change $% | Six Months Ended June 30, 2022 | 2021 | Change $% | |||
|---|---|---|---|---|---|---|---|---|
| Income tax provision | $203 | $43 | $160 | 372% | $332 | $73 | $259 | 355% |
The increase in the income tax provision for the three and six months ended June 30, 2022, as compared to the three and six months ended June 30, 2021, was primarily related to the recognition of uncertain tax positions.
Liquidity and Capital Resources
Our principal sources of liquidity are our existing cash and cash equivalents and cash from operations. Our liquidity and capital structure are evaluated regularly within the context of our annual operating and strategic planning process. We consider the liquidity necessary to fund our operations, which include working capital needs, investments in research and development, investments in inventory and instrument sets to support our customers, as well as other operating costs. Our future capital requirements will depend on many factors including our rate of revenue growth, the timing and extent of spending to support development efforts, the expansion of sales, marketing and administrative activities, and the timing of introductions of new products and enhancements to existing products. As current borrowing sources become due, we may be required to access the capital markets for additional funding. If we are required to access the debt market, we expect to be able to secure reasonable borrowing rates.
Cash and cash equivalents were $107.5 million and $187.2 million at June 30, 2022, and December 31, 2021, respectively. We believe that our existing funds, cash generated from our operations and our existing sources of and access to financing are adequate to satisfy our needs for working capital, capital expenditure and debt service requirements, and other business initiatives we plan to strategically pursue.
Summary of Cash Flows
(in thousands)
| Cash (used in) provided by: | Six Months Ended June 30, 2022 | 2021 |
|---|---|---|
| Operating activities | $(52,050) | $(35,110) |
| Investing activities | (27,817) | (124,847) |
| Financing activities | 771 | 128,769 |
| Effect of exchange rate changes on cash | (682) | 4 |
| Net decrease in cash and cash equivalents | $(79,778) | $(31,184) |
Operating Activities
We used cash of $52.1 million from operating activities for the six months ended June 30, 2022. The cash used in operating activities primarily related to costs associated with the continued expansion of our business and inventory purchases, offset by the timing of cash payments and receipts.
Investing Activities
We used cash of $27.8 million in investing activities for the six months ended June 30, 2022, which is primarily related to the purchase of surgical instruments to support the commercial launch of new products and growth of our business.
Financing Activities
Financing activities provided $0.8 million of cash for the six months ended June 30, 2022, which is related to proceeds from financed insurance and proceeds from warrant exercises.
Debt and Commitments
As of June 30, 2022, we had $316.3 million outstanding under the 2026 Notes. The 2026 Notes accrue interest at a rate of 0.75%, payable semi-annually in arrears on February 1 and August 1 of each year. Prior to maturity in August 2026, the holders of the 2026 Notes may, under certain circumstances, choose to convert their notes into shares of our common stock. Based on the terms we have the option to pay or deliver cash, shares of our common stock, or a combination thereof, when a conversion notice is received.
We assumed the OCEANE convertible bonds issued by EOS in connection with our acquisition of EOS. The OCEANEs bear interest at 6% per year, payable semi-annually in arrears on May 31 and November 30 of each year. Unless either earlier converted or repurchased, the outstanding OCEANEs of $13.0 million (€12.5 million) will mature on May 31, 2023.
We also assumed $5.2 million (€4.8 million) in other debts with the acquisition of EOS that are due in monthly and quarterly installments beginning in 2023 through maturity in 2027.
As of June 30, 2022, we have made $51.2 million in Orthotec settlement payments and we have an outstanding balance of $6.5 million in Orthotec settlement payments (including imputed interest) to be paid by us.
With the acquisition of EOS, we assumed its inventory purchase commitment agreement with a third-party supplier. We are obligated to certain minimum purchase commitment requirements through December 2026. As of June 30, 2022, the remaining minimum purchase commitment under the agreement was $28.9 million.
Contractual obligations and commercial commitments
As of June 30, 2022, there have been no material changes, outside the normal course of business, in our outstanding contractual obligations from those disclosed within the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
Real Property Leases
On April 9, 2021, we entered into a 7-year operating lease agreement for a distribution center which consists of approximately 75,643 square feet of office and warehouse space in Memphis, Tennessee. The term of the lease commenced on May 1, 2021, and will terminate on May 1, 2028, subject to two thirty-six-month options to renew. Base rent under the building lease will be commensurate with our proportionate share of occupancy of the building and will increase annually by 3.0% throughout the remainder of the lease.
With the acquisition of EOS, we assumed its right-of-use assets and leases liabilities in the amount of $4.3 million. EOS occupies its main office in Paris, France. The EOS office in Paris, France is an operating lease that commenced in 2019 and will terminate in September 2028.
On December 4, 2019, we entered into a lease agreement for our headquarters location which consists of 121,541 square feet of office, engineering, and research and development space in Carlsbad, California. The term of the lease commenced on February 1, 2021, and will terminate January 31, 2031, subject to two sixty-month options to renew. Base rent under the lease increases annually by 3.0% throughout the remainder of the lease.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements.
Recent Accounting Pronouncements
Aside from the changes disclosed in Note 2 to the Notes to Condensed Consolidated Financial Statements (Unaudited) under the heading “Recent Accounting Pronouncements,” if any, there have been no new accounting pronouncements or changes to accounting pronouncements during the three months ended June 30, 2022, as compared to the recent accounting pronouncements described in our Annual Report on Form 10-K for the year ended December 31, 2021, that was filed with the SEC.
Forward Looking Statements
This Quarterly Report on Form 10-Q incorporates a number of forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including statements regarding:
- our estimates regarding anticipated operating losses, future revenue, expenses, capital requirements, uses and sources of cash and liquidity, including our anticipated revenue growth and cost savings;
- our ability to achieve profitability, and the potential need to raise additional funding;
- our ability to ensure that we have effective disclosure controls and procedures;
- our ability to meet, and potential liability from not meeting, any outstanding commitments and contractual obligations;
- our ability to maintain compliance with the quality requirements of the U.S. Food and Drug Administration and similar foreign regulatory requirements;
- our ability to market, improve, grow, commercialize and achieve market acceptance of any of our products or any product candidates that we are developing or may develop in the future;
- our ability to continue to enhance our product offerings, and to commercialize and achieve market acceptance of any of our products or product candidates;
- the effect of any existing or future federal, state or international regulations on our ability to effectively conduct our business;
- our business strategy and our underlying assumptions about market data, demographic trends, reimbursement trends and pricing trends;
- our ability to maintain an adequate global sales network for our products, including to attract and retain independent sales agents and direct sales representatives;
- our ability to increase the use and promotion of our products by training and educating spine surgeons and our global sales network;
- our ability to attract and retain a qualified management team, as well as other qualified personnel and advisors;
- our ability to enter into licensing and business combination agreements with third parties and to successfully integrate the acquired technology and/or businesses;
- the impact of global economic and political conditions and public health crises on our business and industry; and
- other factors discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 or any document incorporated by reference herein or therein.
Any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be wrong. They can be affected by inaccurate assumptions and/or by known or unknown risks and uncertainties. Many factors mentioned in our discussion in this Quarterly Report on Form 10-Q will be important in determining future results. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially from expected results.
We also provide a cautionary discussion of risks and uncertainties under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021, and any updates to those risk factors filed from time to time in our subsequent periodic and current reports filed with the SEC. These are factors that we think could cause our actual results to differ materially from expected results. Other factors besides those listed there could also adversely affect us.
Without limiting the foregoing, the words “believe,” “anticipate,” “plan,” “expect,” “estimate,” “may,” “will,” “should,” “could,” “would,” “seek,” “intend,” “continue,” “project,” and similar expressions are intended to identify forward-looking statements. There are a number of factors and uncertainties that could cause actual events or results to differ materially from those indicated by such forward-looking statements, many of which are beyond our control, including the factors set forth under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 and any updates to those risk factors filed from time to time in our subsequent periodic and current reports filed with the SEC. In addition, the forward-looking statements contained herein represent our estimate only as of the date of this filing and should not be relied upon as representing our estimate as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements.
Market risk
As filed, 227 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We have evaluated the information required under this item that was disclosed under Item 7A in our Annual Report on Form 10-K for the year ended December 31, 2021, and there have been no significant changes to this information.
Controls and procedures
As filed, 2,052 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported within the time lines specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, we carried out an evaluation of the effectiveness of our disclosure controls and procedures (as defined in SEC Rules 13a - 15(e) and 15d - 15(e)) as of June 30, 2022. Based on such evaluation, our management has concluded that as of June 30, 2022, our disclosure controls and procedures are effective.
Changes in Internal Control over Financial Reporting
We are in the process of implementing a new enterprise resource planning (“ERP”) system that affects many of our financial processes and is expected to improve the efficiency and effectiveness of certain financial and business transaction processes, as well as the underlying systems environment. There have been no changes to our internal control over financial reporting during the three months ended June 30, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 809 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There have been no material changes to the risk factors described under Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on March 2, 2022, except for those noted below:
The United States has recently experienced historically high levels of inflation. If the inflation rate continues to increase, such as increases in the costs of labor and supplies, it will likely affect our expenses. Additionally, the United States is experiencing an acute workforce shortage, which in turn, has created a hyper-competitive wage environment that may increase our operating costs. To the extent inflation results in rising interest rates and has other adverse effects on the market, it may adversely affect our business, financial condition or results of operations.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-04-01 to 2022-06-30 | $84.2m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 6 months2022-01-01 to 2022-06-30 | $155.1m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2022-04-01 to 2022-06-30 | $28.7m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2022-01-01 to 2022-06-30 | $50.4m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2022-04-01 to 2022-06-30 | $55.5m | us-gaap:GrossProfit |
| Gross profit | 6 months2022-01-01 to 2022-06-30 | $104.7m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2022-04-01 to 2022-06-30 | $72.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2022-01-01 to 2022-06-30 | $142.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-04-01 to 2022-06-30 | −$35.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2022-01-01 to 2022-06-30 | −$77.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-04-01 to 2022-06-30 | $1.4m | us-gaap:InterestExpense |
| Interest expense | 6 months2022-01-01 to 2022-06-30 | $2.9m | us-gaap:InterestExpense |
| Income tax | 3 months2022-04-01 to 2022-06-30 | $203.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2022-01-01 to 2022-06-30 | $332.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-04-01 to 2022-06-30 | −$37.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months2022-01-01 to 2022-06-30 | −$80.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-04-01 to 2022-06-30 | −$0.36 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2022-01-01 to 2022-06-30 | −$0.79 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-04-01 to 2022-06-30 | −$0.36 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2022-01-01 to 2022-06-30 | −$0.79 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-04-01 to 2022-06-30 | 102,849,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2022-01-01 to 2022-06-30 | 101,422,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2022-01-01 to 2022-06-30 | −$52.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2022-01-01 to 2022-06-30 | $26.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-06-30 | $107.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-06-30 | $265.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-06-30 | $511.9m | us-gaap:Assets |
| Current liabilities | At period end2022-06-30 | $121.3m | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2022-06-30 | $313.4m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2022-06-30 | $14.3m | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | At period end2022-06-30 | $14.3m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2022-06-30 | $10.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-22-014850. Last ingested by Listed: Nov 11, 2026, 05:20 ET. Listed shows no prices and gives no investment advice.